Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical and biotechnology industry [3] Core Insights - The recent policy issued by the Ministry of Commerce and eight other departments aims to promote high-quality development in the pharmaceutical retail industry, which is expected to accelerate industry consolidation and benefit leading companies [6][28] - The pharmaceutical and biotechnology index has shown a year-to-date increase of 6.66%, outperforming the CSI 300 index by 5.1 percentage points [11] - The report suggests focusing on high-quality pharmacy enterprises such as Yifeng Pharmacy and Dazhenglin, as the pharmaceutical commercial sector is expected to see improved performance due to favorable policies [33] Market Performance - The pharmaceutical and biotechnology index decreased by 0.39% this week, outperforming the CSI 300 index by 0.23 percentage points, ranking 27th in industry performance [11] - Among sub-sectors, pharmaceutical commerce rose by 4.26%, while chemical pharmaceuticals fell by 1.11% [17] - The top five A-share stocks in the industry this week included *ST Changyao (+70.37%) and Hualan Biological Engineering (+32.21%) [22] Industry News and Policies - The Ministry of Commerce and other departments released an opinion on promoting high-quality development in the pharmaceutical retail industry, proposing 18 specific measures to enhance service quality and industry structure [28] - A loan interest subsidy policy for small and micro enterprises in the pharmaceutical sector was announced, aimed at encouraging investment in manufacturing [28] Company Announcements - Significant announcements include the resignation of executives at various companies and performance forecasts indicating potential losses for some firms due to price reductions and demand declines [36]

证券日报网讯1月27日，华东医药（000963）在互动平台回答投资者提问时表示，据公司初步测算，公 司2025年度经营业绩和财务状况未出现相关法律法规所规定的必须进行业绩预告的情形，也未出现需要 进行业绩快报的情形。公司每个会计年度都聘请专业资产评估机构进行商誉减值测试，具体是否存在商 誉减值事项尚需依据年度审计与评估结果确定，公司将严格根据相关法律法规要求进行披露。 ...

Core Viewpoint - The company Garden Bio (300401) has developed a proprietary chemical synthesis process for Vitamin B6, which features fewer reaction steps and milder conditions, allowing for cost reduction while maintaining yield [1] Group 1: Production Methods - The company’s Vitamin B6 production utilizes a self-developed chemical synthesis process that is efficient and cost-effective [1] - The company is also working on a project for an annual production of 10,000 tons of L-Alanine through fermentation, which is a key raw material for Vitamin B6 production [1]

Core Viewpoint - Yifan Pharmaceutical emphasizes the importance of shareholder concerns and market value management, committing to standardized operations and multiple measures to stabilize its market value [2] Group 1 - The company is focused on enhancing its main business profitability [2] - The company aims to optimize its product structure [2] - The company is working on reducing production costs [2] Group 2 - The company is strengthening information disclosure and investor communication [2] - The company believes that its market value will align with its intrinsic value through effective management [2]

Group 1 - The core viewpoint of the article is that Yifan Pharmaceutical is committed to timely disclosure regarding the new regional sales of Yilishu and will communicate investor concerns about its overseas market performance to management [2] Group 2 - Yifan Pharmaceutical responded to investor inquiries on its interactive platform, indicating that it will follow regulations for any new regional market launches of Yilishu [2] - The company acknowledges the importance of investor feedback regarding the overseas market performance of Yilishu [2]

Group 1 - The company, Lu Kang Pharmaceutical (600789.SH), expects to achieve a net profit attributable to shareholders of the parent company between 110 million to 145 million yuan for the fiscal year 2025 [1] - This represents a decrease of 249.62 million to 284.62 million yuan compared to the previous year [1] - The year-on-year decline in net profit is projected to be between 63.26% to 72.13% [1]

Core Viewpoint - The company has signed a strategic cooperation framework agreement with Hangzhou Derui Zhiyao Technology Co., Ltd. to establish a long-term partnership for CDMO projects, emphasizing mutual benefits and complementary advantages [1] Group 1 - The agreement is a framework agreement and does not involve substantial transactions [1] - The agreement does not constitute a related party transaction [1] - The agreement does not fall under the major asset restructuring regulations as per the listed company management measures [1] Group 2 - The signing of the strategic framework agreement does not require approval from the company's board of directors or shareholders [1]

证券之星消息，1月27日化学制药板块较上一交易日下跌0.97%，广生堂领跌。当日上证指数报收于 4139.9，上涨0.18%。深证成指报收于14329.91，上涨0.09%。化学制药板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 301089 | 拓新药业 | 34.37 | 7.98% | 18.06万 | | 5.92亿 | | 000952 | 广济药业 | 8.26 | 6.03% | 55.28万 | | 4.36亿 | | 300765 | 新诺威 | 40.93 | 5.41% | 12.05万 | | 4.83亿 | | 603229 | 奧翔药业 | 10.45 | 4.40% | - 36.29万 | | 3.70亿 | | 688176 | 亚斯医药 | 14.56 | 4.30% | 17.36万 | | 2.51亿 | | 301263 | 泰恩康 | 34.45 | 3.30% | 11.27万 | | 3.86亿 | | 688 ...

Core Viewpoint - Haisheng Pharmaceutical (002099.SZ) has received approval from the National Medical Products Administration for the marketing application of Diquafosol Sodium, a P2Y2 receptor agonist used in eye drop formulation for the treatment of dry eye disease [1] Group 1 - Diquafosol Sodium acts on the P2Y2 receptors located on the conjunctival epithelium and goblet cell membranes [1] - The mechanism of Diquafosol Sodium involves upregulating intracellular calcium ion concentration, which promotes the secretion of water and mucin, thereby improving symptoms of dry eye [1]

Core Viewpoint - The approval of the sodium diquafosol raw material drug by the National Medical Products Administration enhances the company's product pipeline and competitiveness, although it will not have a significant short-term impact on performance due to pending GMP inspections and various uncertainties regarding production and sales timing [1] Group 1 - The company has received the approval notice for the sodium diquafosol raw material drug, which is packaged in 5kg barrels and meets drug registration requirements [1] - Sodium diquafosol is a P2Y2 receptor agonist, and its eye drops are used for the treatment of dry eye syndrome, with projected sales of 130.89 million yuan in public hospitals in Chinese cities in 2024 [1] - The approval will enrich the company's product pipeline and enhance its competitiveness in the market [1] Group 2 - The company still needs to pass GMP inspections, which introduces uncertainty regarding the short-term impact on performance [1] - The timing and conditions of production and sales are influenced by multiple factors, leading to further uncertainties [1]